Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company dedicated to advancing novel therapies for life-threatening immune and thrombotic conditions. Headquartered in Ponte Vedra Beach, Florida, the company's mission is to develop differentiated biopharmaceutical products that address critical gaps in current acute and chronic anticoagulant therapy, aiming to provide greater predictability, increased stability, more precise control, and fewer bleeding complications for patients.

The company's pipeline includes several clinical-stage assets. Its lead program, CAD-1005, is a Phase 3-ready, first-in-class 12-LOX inhibitor being developed for the treatment of heparin-induced thrombocytopenia (HIT), a severe immune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA), as well as orphan drug status from the European Medicines Agency. Additionally, Cadrenal Therapeutics is advancing tecarfarin, a Phase 3-ready oral vitamin K antagonist for patients with end-stage kidney disease and those with left ventricular assist devices, and frunexian, a parenteral, clinical-stage Factor XIa inhibitor designed for use in acute hospital settings.

Quang X. Pham serves as the Chairman and Chief Executive Officer of Cadrenal Therapeutics. Recent corporate developments include an announcement on July 1, 2026, regarding an up to $8.8 million private placement. The company also announced on June 24, 2026, that its CAD-1005 Phase 2 study was selected for a late-breaking oral presentation at the ISTH 2026 Congress, and on June 18, 2026, its plans to file for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease. On July 10, 2026, the company disclosed the resignation of its Chief Medical Officer, James J. Ferguson III, effective July 31, 2026.